 "Glenmark ties up with Evestra to develop contraceptive")
Glenmark Pharmaceuticals has tied up with Evestra Inc to develop and market a generic version of Merck's female contraceptive product. The companies will file for product approval in financial 2019.
Under the agreement, Evestra will develop generic version of NuvaRing exclusively for Glenmark for the US market and will receive certain milestone payments during various stages of its development, including royalties on net sales, Glenmark said.
"The partnership with Evestra. expands our portfolio into a leading non-daily contraceptive option prescribed for millions of women in the US," Glenmark's North America and Global API President Robert Matsuk said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app